RELAY: Final Overall Survival for Erlotinib + Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC

By sjmartinez • December 3, 2024

Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Nishino K, Yoh K, Shih JY, Chik JY, Moro-Sibilot D, Puri T, Varughese SC, Frimodt-Moller B, Visseren-Grul C, Reck M. RELAY: Final Overall Survival for Erlotinib + Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. J Thorac Oncol. 2024 Nov 30:S1556-0864(24)02495-X. doi: 10.1016/j.jtho.2024.11.032. Epub ahead of print. PMID: 39622410.

Tags: EGFR mutation, erlotinib, Hematology/Oncology, NSCLC, overall survival, Publications, ramucirumab

Relationship Between Perceived COVID-19 Risk and Change in Perceived Breast Cancer Risk: Prospective Observational Study

Baxter-King R, Naeim A, Huang TQ, Sepucha K, Stanton A, Rudkin A, Ryu R, Sabacan L, Vavreck L, Esserman L, Stover Fiscalini A, Wenger NS.[...]

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave[...]

Liquid Biopsy in Hepatocellular Carcinoma: Challenges, Advances, and Clinical Implications

Park J, Lee YT, Agopian VG, Liu JS, Koltsova EK, You S, Zhu Y, Tseng HR, Yang JD. Liquid Biopsy in Hepatocellular Carcinoma: Challenges, Advances,[...]